Analysis: Manufacturer Fees To GPOs Do Not Raise Costs To Providers
This article was originally published in The Gray Sheet
Executive SummaryA new analysis has concluded that fees paid by manufacturers to group purchasing organizations for access to GPO member hospitals do not lead to higher overall costs for hospitals.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.